Foreign Body Ingestion During COVID-19 Lockdown

NCT ID: NCT05261074

Last Updated: 2022-03-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-20

Study Completion Date

2022-10-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ingestion of foreign bodies (FB) is one of the most observed domestic accidents and a frequent reason for consultation in pediatric emergency departments (PED). In the United States, nearly 100,000 ingestions of FB have been recorded by the National Poison Data System (NPDS), which represented the 4th cause of intoxication in 2015.

Ingestion of FB involves very different mechanisms in children and adult patients. Unlike adults, 98% of FB ingestions in children are accidental and involve common objects found at home environment. Ingested FBs are of many types and vary depending on the object composition of the child's environment and supervision. The lockdown for COVID-19 pandemic highly modified children environment and parent supervision. Children remained at home and parents lived at home for teleworking.

In this study, the modifications of children environment that could affect epidemiology of FB ingestion will be evaluated. This is a retrospective study with a sample of around \> 100 children of Louis Mourier hospital from January 1 to December 31, 2019 and from March 1 to May 31, 2020. The total duration of the study is planned for 10 months.

Primary outcomes:

• To determine the role of COVID-19 pandemic linked containment on the prevalence of FB ingestions in children.

Secondary outcomes:

* Describe the epidemiological-clinical, radiological, therapeutic and evolutionary characteristics of the FB consultant's ingestions in the emergency department
* Determine the frequency of endoscopy or surgery
* Determine the factors favoring the use of endoscopic extraction From March 16 to May 10, 2020.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To analyze the impact of COVID-19 lockdown in 2020 on FB ingestion by children, to compare epidemiology of FB ingestion during 3 periods: 2020 lockdown (March to May 2020), the entire 2019 year and March to May 2019. The anonymized data will be entered in Epidata software and data transfer secured using APHP servers.

The variables of interest will include: sex, age at the time of ingestion, type of the FB, single or multiple ingestion, annual period of ingestion, ingestion schedule, existence of a witness, time of arrival at the emergency room, presence and nature of clinical symptoms of ingestion, position of the FB in the digestive tract, complications of this ingestion, x-ray exams used to locate FB need for an extraction gesture, nature of this gesture, completion time, successes and complications of extraction.

The population should have an estimated number of between 100-150 children. Descriptive statistics. The quantitative variables will be described as mean and standard deviation or as median, quartiles, minimum and maximum depending on whether their distribution is Gaussian or not. The qualitative variables will be described in numbers (percentage).

Comparison tests. Qualitative data will be analyzed using Chi2 or Fischer's exact test.

The study was approved by hospital's ethics committee.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Foreign Body Ingestion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention (retrospective study)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children \<15 years old.
* Child who consulted in the pediatric emergency department of Louis-Mourier University Hospital.
* For ingestion of foreign bodies coded in Urqual software.

Exclusion Criteria

* Refusal to participate in the study
* unusable files (\> 20% missing data out of a total of 40 major items),
* Ingestion of CE was suspected but not confirmed,
* Ingestion of caustics or other chemicals,
* Introduced from an FB into the digestive tract by a route other than the oral cavity.
Minimum Eligible Age

1 Day

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jerôme VIALA, MD, PhD

Role: STUDY_CHAIR

Assistance Publique - Hôpitaux de Paris

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Louis Mourier Hospital - Assistance Publique Hopitaux de Paris

Colombes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jerôme VIALA, MD, PhD

Role: CONTACT

+33140035712

Naim DRID, MD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jerome VIALA, MD, PhD

Role: primary

+33140035712

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

APHP-COCE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

ACEs Referral From PED
NCT06574633 COMPLETED NA